IRIS
VICENTI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.499
EU - Europa 5.804
AS - Asia 3.156
SA - Sud America 604
AF - Africa 213
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 16.285
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.370
RU - Federazione Russa 1.400
GB - Regno Unito 1.037
SG - Singapore 1.010
IT - Italia 874
CN - Cina 812
IE - Irlanda 740
BR - Brasile 499
DE - Germania 417
VN - Vietnam 400
SE - Svezia 369
HK - Hong Kong 312
FR - Francia 309
FI - Finlandia 176
UA - Ucraina 168
IN - India 143
KR - Corea 141
ZA - Sudafrica 121
ES - Italia 79
BD - Bangladesh 73
CA - Canada 60
MX - Messico 43
JP - Giappone 40
TR - Turchia 40
AR - Argentina 38
NL - Olanda 38
PL - Polonia 36
IQ - Iraq 34
BE - Belgio 33
NG - Nigeria 31
AT - Austria 30
PK - Pakistan 17
CZ - Repubblica Ceca 16
UZ - Uzbekistan 16
ID - Indonesia 15
KE - Kenya 14
LT - Lituania 13
EC - Ecuador 12
IR - Iran 12
PY - Paraguay 12
MA - Marocco 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
CI - Costa d'Avorio 9
CL - Cile 9
CO - Colombia 9
JM - Giamaica 9
SA - Arabia Saudita 9
DK - Danimarca 8
EG - Egitto 8
LV - Lettonia 8
EE - Estonia 7
GR - Grecia 7
AZ - Azerbaigian 6
JO - Giordania 6
NP - Nepal 6
PH - Filippine 6
TH - Thailandia 6
AU - Australia 5
BO - Bolivia 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
PA - Panama 5
PE - Perù 5
PT - Portogallo 5
BG - Bulgaria 4
ET - Etiopia 4
GE - Georgia 4
SN - Senegal 4
TW - Taiwan 4
AL - Albania 3
HN - Honduras 3
IL - Israele 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
MY - Malesia 3
PS - Palestinian Territory 3
RO - Romania 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BW - Botswana 2
BY - Bielorussia 2
CR - Costa Rica 2
CY - Cipro 2
DZ - Algeria 2
GY - Guiana 2
HU - Ungheria 2
KH - Cambogia 2
LU - Lussemburgo 2
NO - Norvegia 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
EU - Europa 1
Totale 16.270
Salva come PNG Salva come JPEG
Città #
Southend 848
Dallas 808
Dublin 733
Singapore 577
Fairfield 529
Ashburn 449
Chandler 443
San Jose 380
Moscow 375
Santa Clara 366
Hong Kong 298
Siena 233
Woodbridge 225
Beijing 224
Munich 222
Seattle 217
Ann Arbor 216
Houston 198
Cambridge 187
Hefei 174
Wilmington 167
Seoul 137
New York 129
Ho Chi Minh City 128
Jacksonville 128
Los Angeles 128
Council Bluffs 124
Princeton 117
Johannesburg 115
Helsinki 93
Lauterbourg 90
Hanoi 88
Milan 78
The Dalles 73
Rome 72
Bengaluru 50
São Paulo 48
Boardman 44
Málaga 44
San Diego 43
Orem 42
Shanghai 42
Buffalo 40
Florence 40
San Mateo 38
London 36
Tokyo 32
Brussels 31
Frankfurt am Main 31
Redondo Beach 31
Turku 31
Abuja 29
Nanjing 29
Portsmouth 29
Warsaw 29
Nuremberg 26
Lappeenranta 25
Montreal 25
Chennai 23
Chicago 23
Dong Ket 22
Dearborn 21
Denver 20
Manchester 20
Mexico City 20
Stockholm 19
Vienna 19
Brooklyn 18
Columbus 18
Haiphong 17
Toronto 17
Atlanta 16
Düsseldorf 16
Fremont 16
Nanchang 16
San Francisco 16
Rio de Janeiro 15
Da Nang 14
Guangzhou 14
Naples 14
Poplar 14
Amsterdam 13
Changsha 13
Phoenix 13
Baghdad 12
Brescia 12
Dhaka 12
Tashkent 12
Belo Horizonte 11
Hải Dương 11
Mumbai 11
Perugia 11
Redwood City 11
Ankara 10
Newark 10
North Bergen 10
Norwalk 10
Abidjan 9
Brasília 9
Kunming 9
Totale 10.801
Salva come PNG Salva come JPEG
Nome #
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 327
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 326
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 296
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 296
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 292
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 280
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 272
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 272
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 255
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 254
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 253
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 250
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 248
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 243
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 242
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 240
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 239
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 237
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 236
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 234
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 229
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 222
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 219
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 217
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 212
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 209
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 208
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 201
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 200
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 200
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 198
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 198
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 192
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 186
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 184
Serendipitous identification of azine anticancer agents using a privileged scaffold morphing strategy 183
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 183
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 181
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 180
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 179
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 178
Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting 177
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database 176
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 175
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 173
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season 171
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3 167
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 167
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 164
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 162
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 161
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity 160
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 158
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 157
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 156
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 155
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties 153
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 148
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021 148
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 145
Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination 145
Zika virus in west africa: A seroepidemiological study between 2007 and 2012 145
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 144
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 141
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 140
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 140
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 140
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 139
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 138
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 138
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 136
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 135
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 135
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype 129
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 127
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 125
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 123
null 121
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 120
Serum neutralizing activity against b.1.1.7, b.1.351, and p.1 sars-cov-2 variants of concern in hospitalized covid-19 patients 120
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 120
null 114
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 113
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 111
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines 110
Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm) 110
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France) 109
Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021 108
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 85
Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1 84
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 68
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020 62
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 54
Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012 54
null 32
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 28
null 14
null 12
Totale 16.593
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.997
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202185 0 0 0 0 0 0 0 0 0 0 0 85
2021/20221.238 69 136 92 161 66 65 71 71 69 109 110 219
2022/20231.426 78 204 166 164 126 270 69 100 97 61 63 28
2023/20241.197 38 36 101 77 21 307 408 35 8 26 34 106
2024/20252.978 67 99 377 183 288 231 110 207 319 158 295 644
2025/20266.597 476 832 779 899 1.411 241 761 227 285 387 207 92
Totale 16.593